Article By:
Zacks Investment Research
Tuesday, August 29, 2017 1:43 PM EDT
Anthera Pharmaceuticals, Inc. announced positive top-line data from the extension of a phase II BRIGHT-SC study, evaluating key pipeline candidate, blisibimod for treatment of patients with IgA nephropathy (IgAN).